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ABSTRACT
Objective: To identify functional assessment scales used 
in Pompe disease (PD) and to describe their levels of evidence 
and grades of recommendation.
Data source: Systematic review of the functional assess-
ment scales used in PD. Review conducted in the databases 
Medline, Lilacs, Cochrane Central Register of Controlled 
Trials (CCTR), and SciELO including articles (except review 
articles) published between 2000 and 2010. The key-words 
used in Portuguese and English were: glycogen storage 
disease type II, activities of daily living, assessment. The 
articles were classified according to their level of evidence 
and grade of recommendations.
Data synthesis: 14 studies assessing patients ranging 
from newborns to adults were included in the present re-
view (total sample=449). The scales found in the literature 
were: Pediatric Evaluation of Disability Inventory (PEDI) 
and its adapted version for PD (Pompe-PEDI), Alberta 
Infant Motor Scale (AIMS), Rotterdam Handicap Scale 
(RHS), Functional Independence Measure (FIM), Gross 
Motor Function Measure (GMFM), and Peabody Devel-
opmental Motor Scales (PDMS-II). Most studies had level 
of evidence III because they were non-randomized studies. 
The grades of recommendation of the scales were C for 
AIMS and Pompe-PEDI, D for GMFM and PDMS-II; and 
E for RHS and FIM.
Conclusions: Most functional assessment scales used in 
PD show low level of evidence and grade of recommendation. 
The scales showing the highest grade of recommendation (C) 
were the AIMS and Pompe-PEDI used in Pediatrics.
Key-words: glycogen storage disease type II; activities 
of daily living; evaluation.
RESUMO
Objetivo: Identificar as escalas utilizadas para avaliação 
funcional na doença de Pompe (DP) e descrever seu nível de 
evidência e recomendação.
Fontes de dados: Revisão sistemática sobre as escalas de 
avaliação funcional na DP. Pesquisa realizada nos bancos 
de dados Medline, Lilacs, Registro Cochrane de Ensaios 
Controlados Central (CCTR) e SciELO com artigos (ex-
ceto artigos de revisão) publicados entre 2000 e 2010. As 
palavras-chave utilizadas nos idiomas português e inglês 
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foram: doença de depósito de glicogênio tipo II, atividades 
cotidianas, avaliação. Os artigos foram classificados em nível 
de evidência e recomendação.
Síntese dos dados: Foram incluídos 14 estudos que ava-
liaram desde recém-nascidos a adultos (amostra total=449). 
Foram encontradas as seguintes escalas na literatura: Pe-
diatric Evaluation of Disability Inventory (PEDI) e sua forma 
adaptada para DP (Pompe-PEDI), Alberta Infant Motor 
Scale (AIMS), Rotterdam Handiscap Scale (RHS), Functional 
Independence Measure (FIM), Gross Motor Function Measure 
(GMFM) e Peabody Developmental Motor Scales (PDMS-II). 
A maioria dos estudos apresentou nível de evidência III, 
por serem não randomizados. Grau de recomendação das 
escalas: C para AIMS e Pompe-PEDI; D para GMFM e 
PDMS-II; E para RHS e FIM.
Conclusões: A maioria das escalas utilizadas para avaliação 
funcional na DP apresenta baixo nível de evidência e recomen-
dação. As que apresentam melhor grau de recomendação (C) 
são as escalas AIMS e Pompe-PEDI aplicadas em Pediatria.
Palavras-chave: doença de depósito de glicogênio tipo 
II; atividades cotidianas; avaliação.
RESUMEN
Objetivo: Identificar las escalas utilizadas para evaluación 
funcional en la enfermedad de Pompe (EP) y describir su 
nivel de evidencia y recomendación.
Fuentes de datos: Revisión sistemática sobre las escalas 
de evaluación funcional en la EP. Investigaciones realizadas 
en las bases de datos Medline, Lilacs, Registro Cochrane de 
Ensayos Controlados Central (CCTR) y SciELO con artícu-
los (excepto artículos de revisión) publicados entre 2000 y 
2010. Las palabras clave utilizadas en los idiomas portugués 
e inglés fueron: enfermedad de depósito de glucógeno tipo 
II, actividades cotidianas, evaluación. Los artículos fueron 
clasificados en nivel de evidencia y recomendación según 
Cook et al.
Síntesis de los datos: Se incluyeron 14 estudios que eval-
uaron desde recién-nacidos a adultos (muestra total=449). Se 
encontraron las siguientes escalas en la literatura: Pediatric 
Evaluation of Disability Inventory (PEDI) y su forma adaptada 
para 1DP (Pompe-PEDI), Alberta Infant Motor Scale (AIMS), 
Rotterdam Handiscap Scale (RHS), Functional Independence 
Measure (FIM), Gross Motor Function Measure (GMFM) y 
Peabody Developmental Motor Scales (PDMS-II). La mayoría 
de los estudios presentó nivel de evidencia III, por tratarse 
de estudios no randomizados. Grado de recomendación de 
las escalas: C para AIMS y Pompe-PEDI; D para GMFM y 
PDMS-II; E para RHS y FIM.
Conclusiones: La mayoría de las escalas utilizadas para 
evaluación funcional en la EP presenta bajo nivel de evi-
dencia y recomendación. Las que presentan mejor grado de 
recomendación (C) son las escalas AIMS y Pompe-PEDI 
aplicadas en Pediatría.
Palabras clave: enfermedad de depósito de glucógeno 
tipo II; actividades cotidianas; evaluación.
Introduction
Pompe disease (PD), also known as glycogen storage 
disease type II, is an autosomal recessive inheritance disease, 
caused by the deficiency of the acid alpha-glucosidase (GAA) 
enzyme responsible for degradation of lysosomal glycogen. 
This enzyme deficiency results in lysosomal glycogen ac-
cumulation in different tissues, with skeletal, cardiac and 
smooth muscle most prominently involved(1,2). 
The infantile form (infantile-onset Pompe disease) affects 
children in the first months of life, with the following clinical 
manifestations: cardiomyopathy (dilated or hypertrophic), 
hypotonia and muscle weakness of rapid progression. In 
general, the child evolves to death due to cardiorespiratory 
failure in the first year of life. 
The late-onset disease (late-onset Pompe disease) can 
manifest at any age between the 1st year until the 6th 
decade of life. Typically, this late form of the disease does 
not include severe cardiomyopathy and is characterized by 
presenting a slower disease progression than the infantile 
form. Muscle weakness is the main symptom, predomi-
nantly in the proximal muscles with an extensive involve-
ment of the lower limbs, resulting in loss of motor function 
and difficulty in performing daily living activities. With 
disease progression, patients become wheelchair users and 
may become dependent on mechanical ventilation due to 
respiratory failure, which is the main cause of morbidity 
and mortality(2,3). 
Musculoskeletal involvement is characterized by a pro-
gressive replacement of the contractile tissue by a fibrotic 
inactive tissue, causing progressive loss of muscular strength 
with motor function impairment, postural changes and 
the use of compensatory patterns of movement. Secondary 
musculoskeletal impairments include contractures and 
deformities that compromise the function(3,4). The extent 
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and the distribution of muscle weakness depend on the 
severity of the disease. It often involves all members and 
is symmetrical, being greater in the proximal muscles and 
lower limbs(1,4). 
Currently, the treatment of PD is made by enzyme 
replacement therapy (ERT) with the recombinant hu-
man alpha-glucosidase enzyme, approved in 2006 by 
the European Medicines Agency and the Food and Drug 
Administration(3,4). The ERT has provided significant 
improvement in cardiac and skeletal muscle function, pro-
longing survival and reducing mortality(4). However, this 
therapeutic option inflicts the use of specific and validated 
assessment methods, so as to report changes in parameters 
related to disease progression and therapeutic response. 
To monitor the progression of the PD and to guide the 
necessary treatments/interventions, clinical and functional 
assessments are recommended in short periods of time, 
every three to six months in both clinical presentations 
of the disease(3). 
The functional assessment scales for patients with PD 
are poorly known in the medical field. This disease requires 
specific assessment methods to identify and monitor early 
functional changes, as well as to outline appropriate meth-
ods of prevention and treatment for this population. This 
way, this systematic review aimed to identify the functional 
assessment scales that can be used in these cases and their 
level of evidence and recommendation. 
Method
We performed a systematic review about functional as-
sessment scales in children and adults with PD.
The inclusion criteria used in selecting articles for the 
review were the study design (randomized clinical trials, 
cohort, case-control, cross-sectional, case reports and case 
series), the language (Portuguese, English) and the use 
of functional scales used to assess function and functional 
independence of the pediatric and adult population with 
PD, with or without ventilator and mobility devices (e.g. 
wheelchairs) dependence and, with or without enzyme re-
placement therapy. Studies that were focused only on the 
PD, without the use of functional assessment scales or those 
who used them in other genetic diseases related to inborn 
errors of metabolism were excluded.
For the research a manual electronic search was performed 
on Medline, Lilacs Cochrane Central Register of Controlled 
Trials (CCTR) and SciELO with articles (except for review 
articles) published between 2000 and 2010. The key-words 
used in Portuguese and English, respectively, were: doença 
de depósito de glicogênio tipo II, atividades cotidianas, avaliação, 
glycogen storage disease type II, activities of daily living, 
assessment.
The selected articles were classified in level of evidence 
(from I to V, being I the greatest level of evidence) and rec-
ommendation (from A to E, being A the greatest level of 
recommendation) according to Cook et al(5) (Chart 1). The 
analysis of the quality of the articles was performed by two 
independent evaluators who agreed in their classification.
Results
We found 25 studies, of which 14 met the inclusion cri-
teria for this systematic review. These articles assessed from 
newborn to adults, with a total sample of 449 individuals. 
Grades of Recommendation 
A Supported by, at least, two level I investigations
B Supported only by one level I investigation
C Supported only by level II investigations
D Supported by, at least, one level III investigation
E Supported by level IV or V Evidence
Evidence Levels
Level I Randomized trials; great sample size; clear results; low risk of alpha (false-positive) or beta 
(false-negative) errors
Level II Randomized trials; small sample size; uncertain results; moderate to high risk of alpha (false-
positive) or beta (false-negative) errors
Level III Nonrandomized, contemporaneous controls
Level IV Nonrandomized, historical control and experts opinion
Level V Case series; without control subjects and experts opinion
Chart 1 - The grading of recommendations and the levels of evidence for scientific articles, according to Cook et al(5)
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The 11 remaining studies were excluded because they did 
not address functional assessment scales.
The scales found in literature for functional assessment in 
the population with PD were: five studies with the Pediatric 
Evaluation of Disability Inventory (PEDI) scale and its adapted 
form for PD (Pompe-PEDI); seven studies with Alberta 
Infant Motor Scale (AIMS); two studies with Rotterdam 
Handicap Scale (RHS); one study with the Functional 
Independence Measure (FIM); two studies with the Gross 
Motor Function Measure (GMFM) and one with the Peabody 
Developmental Motor Scales (PDMS-II). Five studies used more 
than one scale for functional assessment. The Pompe-PEDI scale 
is the only one specific and validated for this disease(6). 
Most studies presented level III evidence because they 
were nonrandomized studies. Scales grades of recommen-
dation: C for AIMS and Pompe-PEDI; D for GMFM and 
PDMS-II; E for RHS and FIM. Table 1 presents the articles 
found, the classification of the level of scientific evidence 
and the scales of functional assessment used.  
Discussion
The purpose of the functional assessment scales is to 
evaluate and monitor the functional performance, as well 
as to assist in developing methods for prevention and treat-
ment for children and adults with some degree of physical 
disability(7). This systematic review identified the scales 
used for functional assessment of children and adults with 
PD described in literature. It was observed that, so far, six 
scales(6-19) were used, and only the Pompe-PEDI scale is 
specific and validated for this population(1-3).
We found five studies that used PEDI scale and its adapted 
form for Pompe. PEDI is an instrument of broad functional 
assessment that measures the capacity and the performance of 
functional activities, including self-care and mobility. It was 
designed primarily to evaluate children. It can be applied to 
assess adolescents, if their functional abilities are below the 
expected for a 7-year-old child without disabilities. In these 
studies, it was used to assess individuals from 4 months old 
to 32 years old(6,8). 
Haley et al(6) made a study to adapt the PEDI scale 
for individuals with deficiency of the GAA enzyme. The 
authors modified the original scale and included 77 items 
of mobility and 19 items about self-care, which reflect 
the abilities and disabilities present in PD. Parents from 
30 children and young people (mean age 7.7±5.6 years) 
were interviewed by telephone. The score obtained on the 
Pompe-PEDI scale was compared to the PEDI original scale 
and the reliability test was performed with parents of six 
children, and the interclass correlation coefficient (ICC) 
was 0.99 to self-care abilities and 0.98 for mobility skills. 
The Pompe-PEDI scale validity was determined by com-
paring the score of the Gross Motor Function Classification 
System (GMFCS), which is a standardized system with 
five levels, representing the degrees of limitation of gross 
motor function. The authors demonstrated the validity of 
the Pompe-PEDI scale to discriminate differences in motor 
function, when compared with the GMFCS. As a result of 
Design Sample Scale
Haley et al(6) Level III 30 children and adolescents from 0.5–22.1* years PEDI
Haley, Fragala e Skrinar(7) Level III 30 children and adolescents from 0.5–22.1* years Pompe-PEDI
Haley et al(8) Level IV 26 children from 0.4-14* years Pompe-PEDI
Winkel et al(9) Level III 2 children and 1 adult from 11-32* years PEDI GMFM
Kishnani et al(10) Level II 18 children from 4.6±1.7** months Pompe-PEDI AIMS
Kishnani et al(11) Level II 18 children from 4.6±1.7** months AIMS
Klinge et al(12) Level III 2 children from 3.1 and 5.9 months AIMS
Klinge et al(13) Level III 2 children from 14.0 and 16.8 months AIMS
Van den Hout et al(14) Level III 4 children from 2.5–8.0* months AIMS
But et al(15) Level V 1 child of 5.5 months AIMS
Chien et al(16) Level III 6 children from 7–40* days AIMS PDMS-II
Hagemans et al(17) Level IV 257 adults from 48±13** years RHS
Hagemans et al(18) Level IV 52 adults from 48±16** years RHS
Case et al(19) Level V 1 adult of 63 years GMFM FIM
Table 1 - Classification of the studies that used scales for functional assessment of the Pompe disease
PEDI: Pediatric Evaluation of Disability Inventory; GMFM: Gross Motor Function Measure; AIMS: Alberta Infant Motor Scale; PDMS-II: Peabody 
Developmental Motor Scale; RHS: Rotterdam Handicap Scale; FIM: Functional Independence Measure; *age in minimum-maximum; **age in 
mean±standard deviation
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the study, Pompe-PEDI scale proved to be a valid instru-
ment to assess and monitor functional changes in children 
and young people with PD.
In another study, Haley, Fragala e Skrinar(7) assessed the 
degree of physical disability of these children and adoles-
cents through the application of the Pompe-PEDI scale 
by telephone interviews. To estimate the functional delay, 
authors used the original PEDI scale to calculate the age-
appropriate score in the categories mobility and self-care. 
The two scales, original and adapted, served as a basis to 
create a computer-adapted test to reduce the evaluation 
time(8). In this study, authors evaluated the score obtained 
in the functional assessment of children from 4 months 
old to 14 years from two previous studies(7,8): 26 children 
with com PD in which the Pompe-PEDI scale was used 
and 373 children with other diseases, who participated 
in the study of development and standardization of the 
PEDI scale.
Two other studies(9,10) used the PEDI and Pompe-PEDI 
scales to assess the effects of replacement therapy with recom-
binant GAA in motor function. The first is a pilot follow-up 
study(9) that assessed three individuals with late-onset PD 
(aged 11, 16 and 32 years), in which the GMFM scale was 
also applied to assess the gross motor skills. The second is 
a randomized controlled multicenter study(10) that applied 
the Pompe-PEDI scale with the AIMS in 18 children (mean 
age of 4.6±1.7 months) seriously affected by the classical 
infantile form of PD. 
The AIMS is an instrument used to assess motor skills 
acquired from birth to 18 months old. In a study(11) ex-
tending the work of Kishnani et al(10), in which the effects 
of long-term continuous treatment with the recombinant 
GAA in the same sample of 18 children were described, 
the AIMS was used until the patient reached the maximum 
score on this scale. The age of the last functional evalu-
ation ranged from 16 to 37.6 months, most being above 
the standardized age.
Some studies(12-15) applied the AIMS to assess the ef-
fects of enzyme replacement therapy. Chien et al(16), in 
2009, followed six infants (aged 7 to 40 days of life) of 
a pilot program of neonatal screening during 14 to 33 
months of treatment and applied two assessment scales, 
AIMS and PDMS-II. The first identified motor develop-
mental delay in the sample and the second, greater delay 
in the gross motor function than in the fine. A PDMS-II 
is an assessment scale of the fine and gross motor de-
velopment for infants and children (from 6 months to 6 
years of age), consisting of four subtests of gross motor 
function and two of fine motor function.
The Rotterdam Handicap Scale is a short scale that assess-
es the level of independence in the daily activities of patients 
with neuromuscular disorders, used in two studies(17,18). The 
cross-sectional follow-up study(18) applied a questionnaire 
to a sample of 52 individuals aged above 18 years (mean 
48±16 years) after 1 and 2 years of the beginning of the 
research project. Another prospective cross-sectional study(17) 
evaluated the applicability of the RHS in individuals with 
PD. We also analyzed the responses in a questionnaire in 
a sample of 257 individuals aged above 18 years (mean of 
48±13 years). Reliability test was used with a subgroup of 
29 individuals who completed the RHS twice in the interval 
of approximately one month (ICC=0.94), recommending 
its use in PD.
In a case report(19) of a 63-year-old woman affected 
by the late-onset Pompe disease, who received enzyme 
replacement therapy for 2 years, her functional evalua-
tion was performed by the GMFM and FIM scales. The 
latter is widely used in various diseases that cause func-
tional alterations and evaluates the overall performance 
in activities of daily living, assessing both motor and 
cognitive functions.  
In the pediatric population, the scales were more fre-
quently applied were the AIMS, particularly in infants, and 
the PEDI and Pompe-PEDI scales in older children and 
young people with functional capacity lower than expected 
for a 7-year-old child. In adult patients, the RHS was the 
most commonly used scale. 
The functional assessment scales in PD were used pri-
marily to assess the effects of enzyme replacement thera-
pies.  However, they can also be indicated to evaluate the 
functional performance before and after the institution of 
rehabilitation programs.  
Conclusion
Most scales used for PD functional assessment present 
a low level of evidence and  recommendation. Those with 
the best grade of recommendation (C) are the AIMS and 
Pompe-PEDI scales, applied to Pediatrics.
Only the Pompe-PEDI scale is specific for the func-
tional assessment of PD. Only the Rotterdam Handicap 
Scale had its applicability assessed in patients with this 
disease, however, it is limited for use in individuals aged 
over 18 years.
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